Abstract
IntroductionIn July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe.AimUsing a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection.MethodsIndividuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination.ResultsOverall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms.ConclusionsVE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.
| Original language | English |
|---|---|
| Number of pages | 13 |
| Journal | Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin |
| Volume | 27 |
| Issue number | 21 |
| DOIs | |
| Publication status | Published - 26 May 2022 |
Bibliographical note
Funding Information:This project received funding from the European Centre for Disease Prevention and Control (ECDC) under the contract ECD.11486.
Funding Information:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673.
Publisher Copyright:
© 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- COVID-19/epidemiology
- COVID-19 Vaccines
- Europe/epidemiology
- Humans
- Influenza Vaccines
- Influenza, Human/prevention & control
- Primary Health Care
- SARS-CoV-2
- Vaccination
Fingerprint
Dive into the research topics of 'Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver